Good News | Annoroad passed the 2019 EMQN proficiency verification project with full marks

Recently, the European Molecular Genetics Quality Network (EMQN) released its 2019 BRCA Ovarian (Germline) competency assessment report, and Annoroad once again passed the quality evaluation with full marks, which witnessed the standardization and accuracy of each link from gene detection to clinical annotation with strength.


A total of 316 laboratories (266 in 2018) participated in this external quality assessment, and the germline mutations of the BRCA1/BRCA2 genes in the three samples (case1, case2, case3) issued were tested. It is reported that this project is an EQA project carried out by EMQN to evaluate the ability of global genetic diagnosis laboratories to detect and interpret BRCA germline mutations. The project evaluation involves three scoring indicators: Genotyping, Interpretation, Patient Identifiers and Clerical Accuracy. Annoroad received a maximum score of 2.00 for the three indicators, which was higher than the global average. The achievement of full marks reflects Annoroad's superior technical and professional strength in gene mutation detection, clinical genetic interpretation and analysis, clinical report standardization, etc.


Since its establishment, Annoroad has demonstrated strong technical advantages in the field of tumor clinical detection based on a high-throughput sequencing platform. This time, it passed the EMQN external quality assessment with full marks, which not only demonstrated its strength of tumor detection, but also set a higher benchmark in the industry. In the future, Annoroad will continue to explore high-quality points, pursue perfection, and repay the trust of doctors and patients with high-quality and high-standard services.


Copyright © Annoroad Gene Technology 京ICP备12029022号-1